Biolinerx Stock Filter Stocks by Fundamentals
| BLRX Stock | USD 0.32 0.23 41.82% |
BioLineRx fundamentals help investors to digest information that contributes to BioLineRx's financial success or failures. It also enables traders to predict the movement of BioLineRx Stock. The fundamental analysis module provides a way to measure BioLineRx's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioLineRx stock.
BioLineRx | Shares Owned by Institutions |
BioLineRx Current Valuation Drivers
We derive many important indicators used in calculating different scores of BioLineRx from analyzing BioLineRx's financial statements. These drivers represent accounts that assess BioLineRx's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of BioLineRx's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 22.8M | 43.3M | 92.2M | 34.5M | 104.2M | 68.4M | |
| Enterprise Value | 27.9M | 34.2M | 83.8M | 36.3M | 111.5M | 117.1M |
BioLineRx Institutional Holders
Institutional Holdings refers to the ownership stake in BioLineRx that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of BioLineRx's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing BioLineRx's value.| Shares | Two Sigma Securities, Llc | 46.2 K | Orin Green Financial, Llc | 2024-09-30 | 43 K | Geode Capital Management, Llc | 2024-06-30 | 40 K | Rathbone Brothers Plc | 2024-06-30 | 39.8 K | Geneos Wealth Management Inc | 2024-06-30 | 38.5 K | Gradient Investments | 2024-09-30 | 30 K | Rhumbline Advisers | 2024-06-30 | 25.7 K | Weaver Consulting Group | 2024-06-30 | 16.9 K | Cutter & Co Brokerage, Inc. | 2024-09-30 | 16.7 K | Alyeska Investment Group, L.p. | 2024-06-30 | 2 M | Cvi Holdings Llc | 2024-06-30 | 815.7 K |
BioLineRx Fundamentals
| Return On Equity | -1.72 | ||||
| Return On Asset | -0.35 | ||||
| Profit Margin | (1.77) % | ||||
| Operating Margin | (1.07) % | ||||
| Current Valuation | 25.53 M | ||||
| Shares Outstanding | 79.94 M | ||||
| Shares Owned By Insiders | 8.53 % | ||||
| Shares Owned By Institutions | 3.09 % | ||||
| Number Of Shares Shorted | 1.06 M | ||||
| Price To Earning | (3.88) X | ||||
| Price To Book | 1.85 X | ||||
| Price To Sales | 2.01 X | ||||
| Revenue | 4.8 M | ||||
| EBITDA | (57.06 M) | ||||
| Net Income | (60.61 M) | ||||
| Cash And Equivalents | 43.15 M | ||||
| Cash Per Share | 0.90 X | ||||
| Total Debt | 11.59 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 4.58 X | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (22.61 M) | ||||
| Short Ratio | 2.39 X | ||||
| Earnings Per Share | (0.45) X | ||||
| Price To Earnings To Growth | 0.20 X | ||||
| Target Price | 9.83 | ||||
| Number Of Employees | 79 | ||||
| Beta | 0.87 | ||||
| Market Capitalization | 34.33 M | ||||
| Total Asset | 63.92 M | ||||
| Retained Earnings | (390.61 M) | ||||
| Working Capital | 16.33 M | ||||
| Current Asset | 48.18 M | ||||
| Current Liabilities | 3.14 M | ||||
| Net Asset | 63.92 M |
About BioLineRx Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioLineRx's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioLineRx using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioLineRx based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BioLineRx Stock Analysis
When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.